Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease

Fig. 2

Progression-free survival for xentuzumab plus everolimus and exemestane versus everolimus and exemestane. A According to independent assessment. B According to investigator assessment. C Subgroup analysis of progression-free survival by independent assessment. D Subgroup analysis of progression-free survival by investigator assessment. CI, confidence interval; Ev, everolimus; Ex, exemestane; HR, hazard ratio; Plc, placebo; Xe, xentuzumab

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us